TD Cowen Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steve Scala maintains a Hold rating on Bristol-Myers Squibb (NYSE:BMY) and raises the price target from $53 to $59.
October 07, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Steve Scala maintains a Hold rating on Bristol-Myers Squibb and raises the price target from $53 to $59, indicating a positive outlook.
The increase in price target from $53 to $59 by TD Cowen suggests a positive outlook for Bristol-Myers Squibb, which could lead to a short-term positive impact on the stock price. However, the Hold rating indicates a neutral stance on immediate buying or selling.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100